You searched for "bladder���"
Update on immunotherapy for non-muscle invasive transitional cell carcinoma of the bladder
Patients with high-risk non-muscle invasive bladder cancer (NMIBC) that have failed Bacillus Calmette-Guérin (BCG) treatment are a difficult group to treat, and many may not be suitable for the preferred treatment option of radical cystectomy. Bladder-preserving treatments for BCG-unresponsive high-risk...
Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?
Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...Nonacus Clinical Services announce partnership with The London Clinic to deliver GALEAS™ Bladder test
Nonacus Clinical Services, the UK laboratory delivering genomic cancer testing services to the NHS and private healthcare providers, recently announced it is working with The London Clinic to help more patients benefit from its non-invasive GALEAS™ Bladder test for cancer....Bladder cancer diagnosis and follow up: A new proven urinary biomarker to support the post COVID-19 recovery phase
Since lockdown began most urologists have been following the advice of BAUS Oncology, to minimise the risk of exposure of patients and staff to potential COVID-19 infection: the result is an increasing backlog of patients requiring tests to determine if...New Stress Urinary Incontinence Device, Efemia Bladder Support, now on NHS prescription
AGHealth, distributors of innovative obstetric and gynaecology devices, are proud to announce that Efemia Bladder Support is now on NHS Prescription, helping improve the lives of women affected by Stress Urinary Incontinence (SUI).
Can PET/CT help in selecting treatment for patients with muscle-invasive bladder cancer more appropriately?
Radical cystectomy is one of the most drastic procedures that urological patients have to undergo with a five-year mortality of around 50% in those with organ-confined disease at presentation. Traditional imaging is with contrast-enhanced computed tomography (CT) but lymphadenectomy often...
